Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Romee, Rizwan  [Clear All Filters]
Journal Article
Vergara-Cadavid J, P Johnson C, Kim HT, Yi A, Sise ME, Leaf DE, Hanna PE, Ho VT, Cutler CS, Antin JH, et al. Clinical Features of AKI in the Early Post-Transplant Period Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2023.
Huselton E, Rettig MP, Campbell K, Cashen AF, Dipersio JF, Gao F, Jacoby MA, Pusic I, Romee R, Schroeder MA, et al. Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. Leuk Res. 2021;110:106713.
Shapiro RM, Kim HT, Ansuinelli M, Guleria I, Cutler CS, Koreth J, Gooptu M, Antin JH, Kelkar AH, Ritz J, et al. Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse. Blood Adv. 2023.
Bae J, Kitayama S, Herbert Z, Daheron L, Kurata K, Keskin D, Livak K, Li S, Tarannum M, Romee R, et al. Differentiation of BCMA-specific induced pluripotent stem cells into CD8ab+ T cells targeting myeloma. Blood. 2023.
Shapiro RM, Birch GC, Hu G, Cadavid JVergara, Nikiforow S, Baginska J, Ali AK, Tarannum M, Sheffer M, Abdulhamid YZ, et al. Expansion, persistence, and efficacy of donor memory-like NK cells infused for post-transplant relapse. J Clin Invest. 2022.
Maia A, Tarannum M, Romee R. Genetic Manipulation Approaches to Enhance the Clinical Application of NK Cell-Based Immunotherapy. Stem Cells Transl Med. 2023.
Ho VT, Kim HT, Brock J, Galinsky I, Daley H, Reynolds CG, Weber A, Pozdnyakova O, Severgnini M, Nikiforow S, et al. GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized double blinded phase 2 trial. Blood Adv. 2021.
Chin K-K, Kim HT, Inyang E-A, Ho V, Koreth J, Romee R, Gooptu M, Shapiro R, Antin J, Soiffer R, et al. Ibrutinib in Steroid-Refractory Chronic Graft-Versus-Host Disease, a Single-Center Experience. Transplant Cell Ther. 2021.
Dong H, Ham JDongjoo, Hu G, Xie G, Vergara J, Liang Y, Ali A, Tarannum M, Donner H, Baginska J, et al. Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia. Proc Natl Acad Sci U S A. 2022;119(25):e2122379119.
Solomon SR, St Martin A, Zhang M-J, Ballen K, Bashey A, Battiwalla M, Baxter-Lowe LAnn, Brunstein C, Chhabra S, Perez MAngel Diaz, et al. Optimal donor for African Americans with hematologic malignancy: HLA-haploidentical relative or umbilical cord blood transplant. Biol Blood Marrow Transplant. 2020.
Singh A, Dandoy CE, Chen M, Kim S, Mulroney CM, Kharfan-Dabaja MA, Ganguly S, Maziarz RT, Kanakry CG, Kanakry JA, et al. Post-Transplant cyclophosphamide is associated with increase in Non-CMV Herpesvirus infections in Acute leukemia and MDS patients. Transplant Cell Ther. 2021.
Maurer K, Ho VT, Inyang E, Cutler CS, Koreth J, Shapiro RM, Gooptu M, Romee R, Nikiforow S, Antin JH, et al. Posttransplant cyclophosphamide vs tacrolimus-based GVHD prophylaxis: lower incidence of relapse and chronic GVHD. Blood Adv. 2023.
Garcia JS, Kim HT, H Murdock M, Ansuinelli M, Brock J, Cutler CS, Gooptu M, Ho VT, Koreth J, Nikiforow S, et al. Prophylactic maintenance with venetoclax/azacitidine after reduced intensity conditioning allo-transplant for high risk MDS and AML. Blood Adv. 2024.
Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala J, Jagasia M, Pavletic S, Majhail NS, Weisdorf D, et al. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2020.